
A Rapidly Growing National Leader In Home-Based Clinical Care.

Investor Presentation:
NASDAQ: VMD



November 2026

Disclaimers

Disclaimers and Other Important Information

This presentation (the "Presentation") about VieMed Healthcare, Inc. ("VieMed" or the "Company") is dated November 2026. It presents information in a summary form and does not purport to be complete. The data contained herein is derived from various internal and external sources. This Presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. No representation or warranty, express or implied, is made or given by or on behalf of VieMed or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. VieMed does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The contents of this Presentation are not to be construed as legal, financial or tax advice. This Presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of VieMed in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Recipients of this Presentation who are considering acquiring securities of VieMed are referred to the entire body of publicly disclosed information regarding VieMed. The information is subject to material updating, revision and further amendment, and is qualified entirely by reference to VieMed's publicly disclosed information.

Forward Looking Statements

Certain statements contained in this Presentation may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's 2026 net revenue, Adjusted EBITDA and net capital expenditure guidance, anticipated patient and revenue growth, expected operating leverage, technology and personnel investments, capital allocation priorities, future acquisitions, plans for geographic expansion and product rollouts, expected benefits from regulatory developments, industry trends and secular tailwinds, quarterly revenue cadence, share repurchases and future cash generation, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect VieMed's current views and intentions with respect to future events, and current information available to VieMed, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; changes in U.S. trade policies and retaliatory responses from other countries, including tariffs; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; difficulty integrating newly acquired businesses; the impact of new laws and regulations and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns; the use of artificial intelligence technologies; as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in VieMed's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including VieMed's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedarplus.ca. Should any factor affect VieMed in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, VieMed does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this Presentation are made as of the date of this Presentation and VieMed undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

This Presentation contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company's non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics: highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company's future GAAP results.


Market and Industry Data

Industry and market data used in this Presentation is unaudited and has been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. VieMed has not independently verified the data obtained from these sources and cannot assure you of the data's accuracy or completeness. This data is subject to change and cannot always be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey of market or industry data. You are cautioned not to give undue weight to such industry and market data.

Non-GAAP and Other Financial Information

This Presentation includes references to financial measures that are calculated and presented on the basis of methodologies other than in accordance with generally accepted accounting principles in the United States of America ("GAAP"), including the measures Adjusted EBITDA and free cash flow. A reconciliation of these non-GAAP financial measures to the nearest GAAP measures can be found in the Appendix to this Presentation.

An innovative, national in-home healthcare leader built on clinical excellence...



Built a Platform Around Complex Respiratory Services

Home-based care platform built on the reputation of clinical excellence in ventilation. Now leveraging our core platform to include sleep, oxygen, airway clearance and women's health.



Extensive Nationwide Reach

Serving over 223,000 patients with a capex-light business model in all 50 states.



Innovative At-Home Healthcare

High-touch and high-tech services care model drives cost reduction, increases patient satisfaction and reduces rehospitalizations.



Robust Growth and Financial Performance

26% compound annual revenue growth rate since public listing, $26M TTM FCF[1] at 3Q26, and no net debt.

Founded in 2006 • Public since 2017 • Headquartered in Lafayette, Louisiana

(1) See reconciliation of Free Cash Flow in Appendix.

…led by an experienced management team…



Casey Hoyt

CEO and original founder

20+ years with VieMed



Randy Dobbs

Board of Directors, Chairman

10+ years with VieMed



Michael Moore, RRT

President and original founder

20+ years with VieMed



William Frazier, MD

Chief Medical Officer

10+ years with VieMed



Todd Zehnder

Chief Operating Officer

10+ years with VieMed



Trae Fitzgerald

Chief Financial Officer

10+ years with VieMed

>20% Insider Beneficial Ownership

~ $381M Market Cap [1]

Combined management team brings 80+ years of public company experience across GE, Philips, NYSE-listed companies, and Big 4 accounting

(1) Market cap as of 10-28-2026.

...with multiple catalysts driving our growth.

Massively underserved market with a purpose-built clinical model to close the gap

Complex respiratory care and obstructive sleep apnea remain meaningfully underdiagnosed and undertreated. VieMed's high-touch, technology-enabled approach is designed to reach patients where traditional providers cannot.

A vital link between patients, providers, and payors with measurable outcomes

Our clinical care model improves patient compliance, reduces hospitalizations, and drives payor value. Designed to create lasting relationships and a defensible competitive position.

Proven growth platform with a broadening service mix


Organic and inorganic expansion has diversified VieMed well beyond our ventilation roots. Our entry into women’s health is the most recent example of leveraging shared infrastructure for capital-light growth into adjacent markets.

Regulatory tailwinds favor our model

The shift toward home-based care, efficiency, compliance, and transparency plays directly to VieMed's strengths. We are uniquely positioned to succeed in this environment.

Complex respiratory care is the foundation of our business...

Vent Patients on Service[1]



(1) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.

Attractive Unit Economics

Monthly Reimbursement	**~$1,050**
Avg. Length of Stay	**~17 months**
Rental Structure	**Uncapped**
Service Model	**24/7 RT included**
Coverage	**Medicare + most plans**

...serving a population that is massively underserved...


25 Million (estimated) people in the U.S. have COPD

2,500,000 or 10% have stage 4 COPD


1,250,000 or 50% of those with stage 4 COPD develop chronic respiratory failure becoming candidates for our therapy

Approximately 60,000 annual Medicare beneficiaries on NIV service[1]

Estimate of 5% market penetration



VIEMED IS SECOND LARGEST PROVIDER[1]



MARKET SHARE HELD BY TOP 10 PROVIDERS[1]

(1) As of 2025 (source: HME Databank)

... through a tech-enabled, clinical model that sets us apart...

Proprietary clinical platform, connecting best-in-class clinical service with best-in-class devices

Increase efficiency of clinicians through improved remote workflow and proactive patient engagement solutions

24/7 Respiratory Therapist
included in service



Increase patient and caregiver engagement

Capture value-based data elements, analysis and insights from patient's home to improve patient outcomes and generate cost savings

...and backed by real-world outcomes.

respiratory MEDICINE Journal Study

June 29, 2022

Early initiation of non-invasive ventilation at home reduces mortality, hospitalizations, and overall health costs

43%
Relative mortality reduction if utilized within 0-7 days

11.6%
Cost reduction if utilized within 0-7 days

$5,484
Cost reduction if utilized within 0-7 days

7.2%
Cost reduction if utilized within 0-15 days

Sample size: 500,000 patients

AJMC

September 15, 2021

Non-invasive ventilation at home reduces mortality in COPD with CRF

31%
Relative reduction in hospital readmissions

38%
Immediate reduction in risk of death with NIV

12%
Relative reduction in mortality after 12 months

16%
Relative reduction in ER visits

Sample size: 36,000 patients

respiratory MEDICINE Journal Study

December 29, 2020

Non-invasive ventilation at home improves survival and decreases healthcare utilization

39%
Relative reduction in all-cause mortality over 7-year period

22%
Relative reduction in the risk of an ER visit

9%
Relative decline in the risk of hospitalizations

Sample size: 45,000 patients

Our unique operating model has opened doors to expand our patient base…

LEAN OPERATING MODEL

No retail storefronts

Minimal brick-and-mortar limited to small distribution hubs

Mobile workforce

Sales reps and RTs operate from GPS-monitored vehicles, delivering care directly to patients' homes

Data-driven location selection

Target areas with high COPD rates, hospitals struggling with length of stay, and rural markets near existing coverage

Lean market entry

New geographies require clinical talent and payer contracts; dual role RTs to start

Technology focus

Focus on products with technology enablement vs. "bent metal"

PRODUCT OFFERINGS

What fits our current national model

Clinician-delivered, remotely monitored services:

- Ventilation therapy
- Airway clearance devices
- Stationary and Portable O_2 concentrators
- PAP therapy & supplies
- Breast pumps & maternal support

Outside our current national model

Heavy-logistics DME requiring storefronts and warehousing:

- Wheelchairs & mobility
- Hospital beds
- Bulky oxygen tanks

Our unique model drives lower overhead, faster geographic expansion, and higher margins than traditional DME competitors.


… and six years later, the numbers tell the story.

Diverse and Reliable Revenue Streams


Ventilation revenue has doubled since 2019, while sales and service revenue grew from 7% to 32% of the revenue mix.

SERVICE MIX

FY 2019




Q3 2026




PAYOR MIX


FY 2019



Q3 2026



Sleep is the clearest example of what that looks like…



(1) PAP Therapy patients represents the number of distinct patients billed for PAP therapy services during each calendar quarter.
(2) Sleep Resupply Patients represents the number of distinct patients who received supplies through our sleep resupply program during each calendar quarter.
(3) American Lung Association

Growth Metrics

↑38%
3Q26 YoY
PAP Patient Growth

↑22%
3Q26 YoY
Resupply Growth

23%
of 3Q26 Net Revenue
(and Growing)

Multiple Tailwinds

Sleep business reached an inflection point following the Philips recall, which created a significant supply gap and drove patients to quality providers. We accelerated our growth through acquisitions of HMP (2023) and Lehan's (2025), building a national PAP therapy and resupply platform. GLP-1s and wearables continue to drive therapy demand.

Addressable Market over 30 million in the United States[3]

...and we're still expanding our reach.

Oxygen Therapy

7% of Revenue [1]

FY 2025 Growth Rate of 8%

- Tankless portable oxygen concentrators
- Device rentals with lifetime caps
- Earlier stages of COPD
- Growing referral channel from vent relationships





Airway Clearance

7% of Revenue [1]

FY 2025 Growth Rate of 18%

- Nebulizers, cough assists, percussion vests
- Complements core respiratory offering
- Natural benefit to certain vent patients
- Expanding clinical evidence base





Women's Health

8% of Revenue [1]

FY 2025 Growth Rate of 100% [2]

- Breast pumps, insurance-covered, ship-to-home
- Nursing supplies and lactation accessories
- Compression garments and postpartum recovery
- Leverages existing payer relationships and ship-to-home infrastructure





Healthcare Staffing


7% of Revenue [1]

FY 2025 Growth Rate of 12%

- Clinical resources to hospitals & agencies
- Supports continuum of care
- Deepens key referral relationships
- Provides operational flexibility

(1) As a percentage of 3Q26 revenue.
(2) Maternal health reflects a partial year contribution following the acquisition of Lehan's Medical Equipment on July 1, 2025.

Growth Strategy



Three engines driving our next chapter.

ORGANIC GROWTH

- Geographic expansion into new target markets
- Densify existing markets
- Women's health national rollout via existing payers
- Scale sleep through technology-enabled operations

INORGANIC GROWTH

- Active M&A pipeline: complementary services
- Proven playbook: HMP, EAMC, Lehan
- Pristine balance sheet supports deal capacity
- Targets: platforms leveraging shared infrastructure

OPERATIONAL LEVERAGE

- AI & technology driving efficiency across lines
- Declining capex intensity (capital-light mix shift)
- Favorable FCF margin mix (sleep/women's health growing faster)
- Shared infrastructure reduces incremental cost per service

Disciplined M&A has accelerated the platform…

Complementary acquisitions leveraging our platform: successfully integrated and accretive

HMP HOME MEDICAL PRODUCTS a VieMed Healthcare Company

June 2023

- Complex respiratory synergies
- Accelerated sleep growth with mature resupply
- Geographic, product, and payor diversity

East Alabama Health HomeMed

April 2024 (JV)

- Referral source and patient base synergies
- Hospital JV partnership model
- Complementary to organic growth

Lehan's Medical Equipment

July 2025

- Chicago market platform with brand equity
- Added women's health to product offering
- Sleep rental, sales, and resupply synergies

What We Look For: Complementary to core | Leverages infrastructure | Expands Offerings | Expands Geography

… and the runway of opportunities is long.

Our infrastructure, clinical expertise, and payor relationships position us to expand into additional complex home-based services as healthcare continues its shift toward home-based care delivery.

SECULAR TAILWINDS

CMS Push to Home

Federal policy favoring home-based care delivery

Aging Population

Accelerating demand for complex home care

Hospital Cost Pressure

Systems seeking lower-cost care partners

Stable Regulatory Environment

Regulatory stability a strength for the industry

The platform we've built has applications well beyond our current product set.

Regulatory Stability: Stable reimbursement environment and a new coverage standard that strengthens our position

A Rate and Coverage Environment Working in Our Favor.

Medicare Reimbursement	**+ 2.0% - 2.8%**	CPI-driven rate increase took effect in January 2026.
Competitive Bidding Program	**2028**	CMS has signaled a more limited program restart in 2028
Competitive Bidding Products	**Excluded**	CMS confirmed in December 2025 that VieMed's core product categories are excluded from the current round.
Vent NCD	**Coverage Stable**	Long awaited NCD for ventilation a signal of CMS' continued support for the complex therapy.

New Coverage Determination: Near-Term Friction, Long-Term Tailwind.


NEAR-TERM

National Coverage Determination ("NCD") issued in June 2025 adds administrative and clinical complexity to ventilation therapy for both initial patient access and ongoing service. These new standards introduce an initial operational lift for suppliers.

LONG-TERM

- ✓ Higher clinical standards strengthens VieMed's competitive position and our 24/7 RT model.
- ✓ Added complexity favors nationally-scaled providers like VieMed.
- ✓ Clear standards provide increased patients access for Commercial and Medicare Advantage payors.

Financial Performance



2025: Record results across the business…

- Net revenues grew 21% Y-o-Y, reaching a new Company record
- Adjusted EBITDA[1] grew 20% Y-o-Y, reaching a new Company record
- Diluted EPS grew 32% Y-o-Y, the 9th consecutive year of positive net income
- Sleep therapy patients increased 62% Y-o-Y and sleep resupply patient count increased 49% Y-o-Y
- Vent patients increased 4% Y-o-Y

$270M
Net Revenue

$61M
Adjusted EBITDA[1]

$28M
Free Cash Flow[1]

$14M
Cash on Hand

$0M
Net Debt

$46M
Credit Facility Availability

9%
Net Capex[1, 2]

9 Yrs
Positive Net Income

1.98M
Shares repurchased

(1) See Appendix for non-GAAP reconciliations.
(2) Expressed as a percentage of net revenue.

…and continued momentum through 3Q 2026...

- 3Q 2026 Revenue increased 12% Y-o-Y, including Lehan in both periods
- Ventilator rental revenue increased 7.4% Y-o-Y and 2.9% sequentially to $37.5M
- 3Q 2026 Adjusted EBITDA totaled $17.1M[1]
- Generated $11.5M of operating cash flow and $4.0M[1] of FCF in 3Q 2026
- PAP therapy patients increased 38% Y-o-Y and sleep resupply patient count increased 22% Y-o-Y

$80.7M
Net Revenue[3]

$17.1M
Adjusted EBITDA[1, 3]

$26M
TTM Free Cash Flow[1]

$10M
Cash on Hand

$0M
Net Debt

$46M
Credit Facility Availability

9%
Net Capex[1, 2, 4]

$4.6M
Net Income Attr. to VMD[3]

796K
Shares Repurchased[4]

(1) See Appendix for non-GAAP reconciliations.
(2) Expressed as a percentage of net revenue.
(3) Quarter to date 3Q 2026.
(4) Year to date 3Q 2026.


...reflected in consistent full-year financial performance...

	FY 12/31/23	FY 12/31/24	FY 12/31/25	2026 Guidance[1]
Net Revenue	**$ 183.0M**	**$ 224.3M**	**$ 270.3M**	**$ 318.0M**
Gross Margin %	61.6%	59.4%	57.5%	
Net Income Attr. to VMD	**$ 10.2M**	**$ 11.3M**	**$ 14.9M**	
Adjusted EBITDA[2]	$ 43.1M	$ 51.1M	$ 61.4M	$ 65.0M
Adjusted EBITDA %	**23.5%**	**22.8%**	**22.7%**	
Free Cash Flow[2]	$ 21.7M	$ 11.6M	$ 28.1M	

As service mix diversifies, gross margins have moderately compressed, Adj EBITDA margins have held steady and free cash flow has expanded with the decline in capex intensity.

(1) Mid-point of 2026 annual guidance ranges. See slide 24 for additional information and commentary about our 2026 annual guidance.
(2) See reconciliations of Adjusted EBITDA and Free Cash Flow in Appendix.

…and a long track record of consistent growth.



(1) 2020, 2021 and 2022 includes $34.3 million, $8.6 million and $2.3 million of COVID-19 sales and services, respectively.
(2) See reconciliation of Adjusted EBITDA in Appendix.
(3) Mid-point of 2026 annual guidance ranges. See slide 24 for additional information and commentary about our 2026 annual guidance.

2026 Guidance & Commentary

Net Revenue	Adjusted EBITDA	Net CAPEX
$316M – $320M	**$64M – $66M**	**8% – 9%**
Full-Year 2026 Guidance	*Full-Year 2026 Guidance*	*of Net Revenue*

Revenue Cadence

- **Q1** Down ~1% sequentially vs. Q4 2025; consistent with seasonal guidance
- **Q2** Up ~4% sequentially vs. Q1 2026; consistent with seasonal guidance
- **Q3** Up ~3% sequentially vs. Q2 2026; consistent with seasonal guidance
- **Q4** Continued sequential revenue growth expected in 4Q

Share Repurchase Program

5% of Shares Outstanding

Our Board has authorized a new share repurchase program representing up to 5% of shares outstanding.

As of 3Q 2026, we repurchased 795,802 common shares at a cost of $7.5 million (excluding taxes), representing an average buyback price of $9.47 per share.

Capital Allocation Strategy

Our cash flow generation supports all three priorities simultaneously

1

INVEST IN ORGANIC GROWTH

Fully funded by operating cash flow. Sleep tech scaling, women's health national rollout, continued geographic expansion.

2

EXECUTE M&A PIPELINE

Complementary acquisitions leveraging our platform. ~$0M net debt, $46M+ facility provides significant capacity.

3

RETURN CAPITAL TO SHAREHOLDERS

4th share repurchase program authorized. Three prior programs returned $26.3M (4.5M shares; $5.79 avg/share).

Why Own VMD

NASDAQ: VMD

1

Proven National Platform with Multiple High-Growth Opportunities

Infrastructure serving 223,000+ patients across all 50 states, built over a decade of disciplined clinical execution. Ventilation anchor and complementary lines; all leveraging shared infrastructure and payor relationships.

2

Regulatory Stability

Regulatory clarity on two fronts: ventilation coverage standards established, competitive bidding overhang removed.

3

Industry Leading Financial Performance

Building on nine straight years of positive net income, our maturing ventilation patient base combined with capital-light service lines are meaningfully expanding FCF.

4

Pristine Balance Sheet with M&A Optionality


$0M net debt, an active acquisition pipeline, and a proven integration playbook for complementary businesses.

5

Disciplined Capital Allocation - Aligned from the Top

Organic growth funded internally. Board has authorized a new share repurchase program. Insiders beneficially own more than 20% of shares outstanding; leadership's interests are squarely aligned with shareholders.

Appendix



Net CAPEX

(expressed in thousands of U.S. Dollars)

For the quarter ended	9/30/26	6/30/26	3/31/26	12/31/25	9/30/25	6/30/25	3/31/25	12/31/24
Purchase of property and equipment	8,616	8,460	6,712	8,737	7,636	8,129	15,483	11,829
Proceeds from sale of property and equipment	(1,154)	(1,174)	(1,227)	(1,125)	(1,671)	(6,402)	(6,953)	(2,881)
Net CAPEX	7,462	7,286	5,485	7,612	5,965	1,727	8,530	8,948
Net Capex % of Net Revenue	**9.2%**	**9.3%**	**7.3%**	**10.0%**	**8.3%**	**2.7%**	**14.4%**	**14.7%**

Liquidity Metrics

(expressed in thousands of U.S. Dollars)

For the period ended	9/30/26	12/31/25	12/31/24
Cash on hand	$ 9,676	$ 13,501	$ 17,540
Working Capital	$ 11,966	$ 7,437	$ 15,554
Long Term Debt	$ 4,510	$ 11,291	$ 3,589

Positioned for growth

- The Company maintains a healthy balance sheet with no net debt as of September 30, 2026, providing significant financial flexibility.
- As of September 30, 2026, the Company had $46 million available under its existing credit facilities, supporting our capital allocation strategy.

Free Cash Flow – Annual

Management believes free cash flow provides investors with useful insight into the company's ability to generate cash, fund growth initiatives, and return capital to shareholders. Free cash flow does not represent residual cash flow available for discretionary expenditures. Free cash flow is defined as net cash provided by operating activities, as reported under U.S. GAAP, less net capital expenditures (Net CAPEX). Net CAPEX is calculated as purchases of property and equipment minus proceeds from the sale of property and equipment in order to reflect both outflows and inflows associated with routine equipment turnover. Historically reported amounts of Free Cash Flow for the year ended December 31, 2023 has been recast to include the effect of proceeds from the sale of property and equipment. This adjustment aligns the calculation with the Company's current presentation methodology and more accurately reflects net cash flows for capital expenditures by accounting for inflows on asset dispositions.

(Expressed in thousands of U.S. Dollars)

For the year ended	12/31/25	12/31/24	12/31/23
Net cash provided by operating activities	$ 51,916	$ 39,089	$ 45,212
Less:			
Purchase of property and equipment	(39,985)	(37,771)	(26,093)
Proceeds from sale of property and equipment	16,151	10,321	2,588
Net CAPEX	(23,834)	(27,450)	(23,505)
Free Cash Flow	**$ 28,082**	**$ 11,639**	**$ 21,707**

Net Capex % of Net Revenue	**8.8%**	**12.2%**	**12.8%**
Net Capex % of Adjusted EBITDA	**38.8%**	**53.7%**	**54.6%**

Free Cash Flow – Trailing Twelve Months

The Company also presents non-GAAP free cash flow for the current quarter and trailing twelve months (TTM) as a supplemental liquidity measure. Free cash flow does not represent residual cash flow available for discretionary expenditures. Trailing twelve months (TTM) free cash flow is calculated by aggregating the last four quarters, each calculated using the methodology as described on the previous slide.

(Expressed in thousands of U.S. Dollars)

	TTM	For the quarter ended			
	9/30/26	9/30/26	6/30/26	3/31/26	12/31/25
Net cash provided by operating activities	$ 53,901	$ 11,487	$ 15,902	$ 8,071	$ 18,441
Less:					
Purchase of property and equipment	(32,525)	(8,616)	(8,460)	(6,712)	(8,737)
Proceeds from sale of property and equipment	4,680	1,154	1,174	1,227	1,125
Net CAPEX	(27,845)	(7,462)	(7,286)	(5,485)	(7,612)
Free Cash Flow	**$ 26,056**	**$ 4,025**	**$ 8,616**	**$ 2,586**	**$ 10,829**

Reconciliation of Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. VieMed's presentation of this financial measure may not be comparable to similarly titled measures used by other companies. Management believes Adjusted EBITDA provides helpful information with respect to VieMed's operating performance as viewed by management, including a view of VieMed's business that is not dependent on the impact of VieMed's capitalization structure and items that are not part of VieMed's day-to-day operations. Management uses Adjusted EBITDA (i) to compare VieMed's operating performance on a consistent basis, (ii) to calculate incentive compensation for VieMed's employees, (iii) for planning purposes, including the preparation of VieMed's internal annual operating budget, and (iv) to evaluate the performance and effectiveness of VieMed's operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating VieMed's operating performance in the same manner as management. The table below is a reconciliation of net income attributable to VieMed Healthcare, Inc., the most directly comparable U.S. GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated. In calculating Adjusted EBITDA, certain items(mostly non-cash) are excluded from net income including depreciation and amortization of capitalized assets, net interest expense, stock-based compensation, transaction costs, impairment of assets, and taxes.

(Expressed in millions of U.S. Dollars)

For the year ended:	2025	2024	2023	2022	2021	2020	2019	2018	2017
Net Income attributable to VieMed Healthcare, Inc.	**$ 14.9**	**$ 11.3**	**$ 10.2**	**$ 6.2**	**$ 9.1**	**$ 31.5**	**$ 8.5**	**$ 9.5**	**$ 7.7**
Add back:									
Depreciation and amortization	28.7	25.3	21.9	15.6	11.3	9.6	6.4	3.8	2.5
Interest expense, net	1.2	0.8	0.4	0.2	0.3	0.5	0.3	0.2	0.3
Loss (gain) on derivative	-	-	-	-	-	-	(0.4)	0.2	0.2
Stock-based compensation(1)	9.1	6.3	5.9	5.2	5.2	4.9	3.9	2.7	0.8
Transaction costs(2)	1.1	0.3	0.5	-	-	-	-	-	-
Impairment of assets(3)	-	2.3	-	-	-	-	-	-	-
Income tax expense (benefit)	6.4	4.8	4.2	2.8	3.4	(5.2)	0.3	0.1	-
Adjusted EBITDA	**$ 61.4**	**$ 51.1**	**$ 43.1**	**$ 30.0**	**$ 29.3**	**$ 41.3**	**$ 19.0**	**$ 16.5**	**$ 11.5**

(1) Represents non-cash, equity-based compensation expense associated with option and RSU awards.
(2) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions.
(3) Represents impairments of the fair value of investment and litigation-related assets.

Reconciliation of Adjusted EBITDA[1]

(Expressed in thousands of U.S. Dollars)

For the quarter ended:	9/30/26	6/30/26	3/31/26	12/31/25	9/30/25	6/30/25	3/31/25	12/31/24
Net Income attributable to VieMed Healthcare, Inc.	**$ 4,638**	**$ 2,764**	**$ 2,582**	**$ 5,639**	**$ 3,513**	**$ 3,157**	**$ 2,625**	**$ 4,316**
Add back:								
Depreciation & amortization	7,718	7,520	7,621	7,570	7,539	6,891	6,613	6,366
Interest expense, net	177	248	305	364	507	132	179	147
Stock-based compensation(2)	2,476	2,032	2,451	2,300	2,180	2,341	2,311	1,521
Transaction costs(3)	-	-	74	139	847	53	85	11
Impairment of assets(4)	-	-	-	-	-	-	-	-
Income tax expense	2,048	1,151	1,278	2,191	1,535	1,713	952	1,881
Adjusted EBITDA	**$ 17,057**	**$ 13,715**	**$ 14,311**	**$ 18,203**	**$ 16,121**	**$ 14,287**	**$ 12,765**	**$ 14,242**

(1) Refer to the previous slide for discussion of Adjusted EBITDA.
(2) Represents non-cash, equity-based compensation expense associated with option and RSU awards.
(3) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions.
(4) Represents impairments of the fair value of investment and litigation-related assets.

Financial and Operational Highlights

(expressed in thousands of U.S. Dollars, except operational information).

For the quarter ended:	9/30/26	6/30/26	3/31/26	12/31/25	9/30/25	6/30/25	3/31/25	12/31/24
Financial Information:								
Revenue	$80,673	$78,097	$75,414	$76,181	$71,914	$63,056	$59,129	$60,695
Gross Profit	$46,192	$45,048	$42,827	$44,103	$41,345	$36,731	$33,279	$36,138
Gross Profit %	57%	58%	57%	58%	57%	58%	56%	60%
Net Income attributable to VieMed Healthcare, Inc.	$4,638	$2,764	$2,582	$5,639	$3,513	$3,157	$2,625	$4,316
Cash and Cash Equivalents (As of)	$9,676	$10,680	$9,762	$13,501	$11,123	$20,016	$10,160	$17,540
Total Assets (As of)	$207,634	$204,224	$197,361	$199,154	$202,360	$184,603	$178,079	$177,069
Adjusted EBITDA(1)	$17,057	$13,715	$14,311	$18,203	$16,121	$14,287	$12,765	$14,242
Operational Information:								
Vent Patients(2)	12,552	12,635	12,089	12,259	12,372	12,152	11,809	11,795
PAP Therapy Patients(3)	43,861	37,825	35,938	34,528	31,891	26,260	22,899	21,338
Sleep Resupply Patients(4)	40,918	37,035	33,661	36,561	33,518	25,246	22,941	24,478

(1) Refer to slides 32-33 in this presentation for the definition of Adjusted EBITDA and a reconciliation to its most comparable GAAP measure.
(2) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.
(3) PAP Therapy Patients represents the number of distinct patients billed for PAP therapy services during each calendar quarter.
(4) Sleep Resupply Patients represents the number of distinct patients who received supplies through our sleep resupply program during each calendar quarter.